
Alexander Nossikoff
@nossikoff
Clinical cardiologist with strong interest in heart failure, VTE, a-fib and imaging. Large experience in TTE/TOE, lung and vascular ultrasound.
ID: 1132162898506051584
25-05-2019 05:54:04
1,1K Tweet
1,1K Followers
669 Following


MOMENTUM 3 trial 5-year follow-up ✅ Centrifugal-flow LVAD vs axial-flow LVAD ➡️ higher overall survival ✔️Less adverse events (stroke, bleeding, and pump thrombosis) American College of Cardiology Sociedad Mexicana de Cardiología SIAC Consejo Interamericano de Falla Cardíaca e HP ANCAM México Jaime Hernandez-Montfort The ISHLT


Physician Wellness in Academic CV Medicine: A Scientific Statement From the American Heart Association ahajournals.org/doi/abs/10.116… Circulation AHA Science Dr. Laxmi Mehta Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 MIЯVΛƬ #IC Erin D. Michos, M.D. Dr. Purvi Parwani Danielle Belardo, MD Ryan P. Daly, MD Anju Bhardwaj MD FACC #CardioTwitter


#DELIVER #Dapa effect across #NYHA class in #HFmrEF & #HFpEF 👉 Consistent ⬇️ #CV_☠️ & #WorseningHF 👉 ⬆️ #QoL in all #NYHA groups 👉 🔝 improvement of #KCCQ in #NYHA III-IV Muthu Vaduganathan @PSJhund Mikhail Kosiborod Shelley Zieroth Javed Butler Mamas A. Mamas 🍀rb.gy/0x3pje






A 👉Time to treatment effects in HF trials. Benefit apparent within 30 d ❗️ B 👉3-step algorithm to implement pharmacological Tx in HFrEF ➡️our review ESC Heart Failure Journal doi.org/10.1002/ehf2.1… Johann Bauersachs Samira Soltani Henry Han European Society of Cardiology Journals





In #heartfailure pts the 5-year risk of cancer 🦀was 9.0 % and did not change from 1997–2001 to 2012–16 ➡️ Survival increased from 56% to 75% in the same period 📈 New sdy by J Bruhn et al in European Society of Cardiology Journals EHJ Editor-in-Chief 📄 academic.oup.com/eurheartj/adva… #CardioTwitter #Cardiology #Cancer

A prospective analysis of #NSTEMI presentation, management and outcomes according to country income classification: does wealth bring health? academic.oup.com/ehjqcco/advanc… #EHJQCCO #CVD #ACS Adam Timmis Prof Chris P Gale Diogo Santos Ferreira



#Olpasiran markedly reduces Lp(a) regardless of baseline concentration. Important implications for phase 3 testing! Michelle O'Donoghue #ACC23


For any range of 🧪 NT-proBNP, there is ⬆️ absolute & relative risk of HF across BMI, w/most clinically meaningful risk diff in those with low-level NT-proBNP elevation (125-<450). In this group, pattern of ⬆️ ARR w/ 💊 #dapagliflozin for obese high risk pts. Sid M. Patel #ACC23


#Iron in #HFrEF 👇 -❌ difference between FCM 🆚FDI and both are safe - NNT: 7👉 23% RRR of CV💀/HF🏥 ❗️ 👉 See our MA in #CRIC Springer Nature led by DavorVuk doi.org/10.1007/s00392… Henry Han Carlos Guizar Alexander Nossikoff Giuseppe Galati Tarek Bekfani, MD, (Priv.-Doz.), MSc, FESC, FHFA Young DGK


